Data Anticipated For Bugula Neritina-Based Bryostatin-1 Drug for Alzheimer’s Disease

Data Anticipated For Bugula Neritina-Based Bryostatin-1 Drug for Alzheimer’s Disease
Another investigational drug trial for the treatment of Alzheimer’s is set to release key findings within the next few months. Neurotrope, Inc. recently announced the closure of their Phase 2a clinical trial of Bryostatin-1, as the last patient enrolled in the study was administered the drug. The trial was conducted under an Investigational New Drug (IND) application. The Phase 2a clinical

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *